These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1257 related articles for article (PubMed ID: 8473405)
21. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Kolligs F; Fehmann HC; Göke R; Göke B Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808 [TBL] [Abstract][Full Text] [Related]
22. Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Gasbjerg LS; Helsted MM; Hartmann B; Jensen MH; Gabe MBN; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK Diabetes; 2019 May; 68(5):906-917. PubMed ID: 30626611 [TBL] [Abstract][Full Text] [Related]
23. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587 [TBL] [Abstract][Full Text] [Related]
24. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561 [TBL] [Abstract][Full Text] [Related]
25. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. Meier JJ; Gallwitz B; Askenas M; Vollmer K; Deacon CF; Holst JJ; Schmidt WE; Nauck MA Diabetologia; 2005 Sep; 48(9):1872-81. PubMed ID: 16010522 [TBL] [Abstract][Full Text] [Related]
26. Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1). Ranganath L; Schaper F; Gama R; Morgan L; Wright J; Teale D; Marks V Diabetes Metab Res Rev; 1999; 15(6):390-4. PubMed ID: 10634963 [TBL] [Abstract][Full Text] [Related]
27. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Greenfield JR; Farooqi IS; Keogh JM; Henning E; Habib AM; Blackwood A; Reimann F; Holst JJ; Gribble FM Am J Clin Nutr; 2009 Jan; 89(1):106-113. PubMed ID: 19056578 [TBL] [Abstract][Full Text] [Related]
32. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion. Jia X; Brown JC; Ma P; Pederson RA; McIntosh CH Am J Physiol; 1995 Apr; 268(4 Pt 1):E645-51. PubMed ID: 7733263 [TBL] [Abstract][Full Text] [Related]
33. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males. Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186 [TBL] [Abstract][Full Text] [Related]
34. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. Vardarli I; Arndt E; Deacon CF; Holst JJ; Nauck MA Diabetes; 2014 Feb; 63(2):663-74. PubMed ID: 24186866 [TBL] [Abstract][Full Text] [Related]
35. The incretin effect does not differ in trained and untrained, young, healthy men. Lund MT; Dalby S; Hartmann B; Helge J; Holst JJ; Dela F Acta Physiol (Oxf); 2014 Mar; 210(3):565-72. PubMed ID: 24354574 [TBL] [Abstract][Full Text] [Related]
36. Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness. Delmeire D; Flamez D; Moens K; Hinke SA; Van Schravendijk C; Pipeleers D; Schuit F Biochem Pharmacol; 2004 Jul; 68(1):33-9. PubMed ID: 15183115 [TBL] [Abstract][Full Text] [Related]
37. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666 [TBL] [Abstract][Full Text] [Related]
38. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Roberge JN; Brubaker PL Endocrinology; 1993 Jul; 133(1):233-40. PubMed ID: 8319572 [TBL] [Abstract][Full Text] [Related]
39. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937 [TBL] [Abstract][Full Text] [Related]
40. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility. Edholm T; Cejvan K; Abdel-Halim SM; Efendic S; Schmidt PT; Hellström PM Neurogastroenterol Motil; 2009 Mar; 21(3):313-21. PubMed ID: 19126188 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]